In the first of a series of special in-pharmatechnologist podcasts Kate Wilber, Image Solutions’ (ISI) director of regulatory Services, Europe discusses the emerging trends in BPO and talks about how it can benefit drugmakers.
Business process outsourcing (BPO) has grown in prominence in the drug industry in recent years as firms have sought more effective ways of completing the regulatory work that is continually required during a pharmaceutical product’s lifecycle.
However, while the BPO principle is straightforward, selecting the most appropriate of the many systems and ways of applying it to regulatory submission and operations processes can be something of a challenge.
But help is at hand for in-Pharmatechnologist subscribers as industry expert Kate Wilber from ISI takes us through the BPO options available to the drug industry and discusses all the latest developments in the field.
Wilber also shares her insights into how the drug industry's use of BPO will develop going forward to make sure can make the best BPO decisions.
In next month's podcast, Kate and I will be discussing regulatory information management (RIM) and how drugmakers can use the approach to track the large amount of data generated each time a drug is filed.